Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Adult Patients With Moderate and Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
443
Start Date
2022-07-14
Completion Date
2026-09
Last Updated
2026-01-05
Healthy Volunteers
No
Conditions
Interventions
Jaktinib Hydrochloride Tablet
Orally administered, twice a day
Locations (1)
139 People's Middle Road
Changsha, Hunan, China